CCXIU — Churchill Capital XI Share News
0.000.00%
Last trade - 00:00- $632.20m
- $630.94m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:51 PM
U.S. STOCKS ON THE MOVE-ChemoCentryx, Syneos Health, Camping World, Vulcan Materials
U.S. RESEARCH ROUNDUP-Comcast, Norfolk Southern, Zendesk
ChemoCentryx Inc reports results for the quarter ended in March - Earnings Summary
Brief: Chemocentryx Reports First Quarter 2021 Financial Results And Recent Highlights
ChemoCentryx Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: ChemoCentryx’s Oral PD-L1 Inhibitor Featured In Poster Presentation At 2021 American Association For Cancer Research Annual Meeting
Brief: ChemoCentryx Announces Appointment Of Susan Kanaya To Board
U.S. RESEARCH ROUNDUP-American Eagle Outfitters, Deere & Co, Willscot Mobile Mini Holdings
Brief: Chemocentryx Reports Qtrly Loss Per Share Of $0.43
Brief: ChemoCentryx Appoints Tausif (‘Tosh’) Butt As Executive Vice President And Chief Operating Officer
U.S. RESEARCH ROUNDUP-Array Technologies, Domino's Pizza, Treehouse Foods
U.S. RESEARCH ROUNDUP-Apartment Income REIT, Paysign, Wesco International
U.S. RESEARCH ROUNDUP-HMS Holdings, Illumina, RealPage
Brief: Chemocentryx And Vfmcrp Provide Topline Results From Accolade Trial Of Avacopan In C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate
Brief: ChemoCentryx Posts Quarterly Loss Per Share $0.35
Brief: Chemocentryx Inc Says ACR Convergence 2020 Will Feature Plenary Session Presentation On Advocate Phase III Trial Results Of Avacopan
Brief: Chemocentryx Says On Oct 29 Entered Into Manufacturing & Supply Agreement With Vifor Fresenius Medical Care Renal Pharma
Brief: Chemocentryx And Vfmcrp Announce European Medicines Agency Has Accepted To Review The Marketing Authorization Application For Avacopan